



Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

August 26, 2025

SOMERSET, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 9, 2025, at 4:05 p.m. ET.

The live webcast will be available to investors and other interested parties by accessing the [Investor Relations](#) section of Legend's website. The webcast replay will be available approximately 48 hours after the webcast.

ABOUT LEGEND BIOTECH

With over 2,800 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI[®], a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Headquartered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI's patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Learn more at www.legendbiotech.com and follow us on [X \(formerly Twitter\)](#) and [LinkedIn](#).

INVESTOR CONTACT:

Jessie Yeung

Tel: (732) 956-8271

jessie.yeung@legendbiotech.com

PRESS CONTACT:

Mary Ann Ondish

Tel: (914) 552-4625

media@legendbiotech.com



Source: Legend Biotech USA Inc.